Structure Therapeutics Reports Highly Positive Phase 2b Data for Oral Obesity Drug Aleniglipron, Advancing to Phase 3

summarizeSummary

Structure Therapeutics reported highly positive Phase 2b clinical trial results for its oral obesity drug, aleniglipron, showing significant weight loss and a favorable safety profile, paving the way for Phase 3 development.

check_boxKey Events

• Positive Phase 2b ACCESS II Results

  Aleniglipron achieved a placebo-adjusted mean weight loss of up to 16.3% at 44 weeks, demonstrating high efficacy for an oral GLP-1RA.

• Improved Tolerability and Safety Profile

  A lower 2.5 mg starting dose significantly reduced adverse event-related discontinuations, and the drug maintained a compelling safety profile with no drug-induced liver injury.

• Advancement to Phase 3

  The company plans an End-of-Phase 2 meeting with the FDA in Q2 2026 and anticipates initiating the Phase 3 program in the second half of 2026.

• Sustained Weight Loss Observed

  Interim data from the ACCESS Open-Label Extension study showed continued weight loss up to 16.2% at 56 weeks, with no evidence of a plateau.

auto_awesomeAnalysis

Structure Therapeutics announced compelling topline results from its Phase 2 ACCESS II trial for aleniglipron, an oral GLP-1 receptor agonist for obesity. The drug demonstrated significant placebo-adjusted mean weight loss of up to 16.3% at 44 weeks, positioning it as a potential best-in-class oral GLP-1RA with efficacy comparable to injectable therapies. The data also highlighted an improved tolerability profile with a lower starting dose and a strong safety record, with no evidence of drug-induced liver injury. These robust results provide a strong foundation for advancing aleniglipron into Phase 3 clinical development, with an FDA meeting scheduled for Q2 2026 and Phase 3 initiation anticipated in 2H 2026. This significantly de-risks the company's lead asset and strengthens its competitive position in the lucrative obesity market.